[Effect of mexidol (2-ethyl-6-methyl-3-oxypyridine succinate) on the quality of life and depressive symptoms in women with rheumatoid arthritis].
A prospective, randomized controlled study of the effects of 2-ethyl-6-methyl-3-oxypyridine succinate (mexidol) on the dynamics of articular syndrome, quality of life, and clinical manifestations of depression has been performed in a group of 62 women with rheumatoid arthritis diagnosis during therapy for two weeks. The use of mexidol in the complex treatment contributed to a decrease of the intensity of rheumatoid inflammation, reduction in the severity of depressive symptoms, and improvement of the functional status and quality of life.